Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Surface Oncology

Nasdaq:SURF
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SURF
Nasdaq
$51M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Surface Oncology has significant price volatility in the past 3 months.
SURF Share Price and Events
7 Day Returns
8.4%
NasdaqGM:SURF
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-62.1%
NasdaqGM:SURF
0%
US Biotechs
-11.5%
US Market
SURF Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Surface Oncology (SURF) 8.4% -32% -14.6% -62.1% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • SURF underperformed the Biotechs industry which returned 0% over the past year.
  • SURF underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Surface Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Surface Oncology. This is due to cash flow or dividend data being unavailable. The share price is $1.81.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Surface Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Surface Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:SURF PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.97
NasdaqGM:SURF Share Price ** NasdaqGM (2020-03-27) in USD $1.81
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Surface Oncology.

NasdaqGM:SURF PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SURF Share Price ÷ EPS (both in USD)

= 1.81 ÷ -1.97

-0.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Surface Oncology is loss making, we can't compare its value to the US Biotechs industry average.
  • Surface Oncology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Surface Oncology's expected growth come at a high price?
Raw Data
NasdaqGM:SURF PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-14.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Surface Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Surface Oncology's assets?
Raw Data
NasdaqGM:SURF PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.03
NasdaqGM:SURF Share Price * NasdaqGM (2020-03-27) in USD $1.81
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:SURF PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SURF Share Price ÷ Book Value per Share (both in USD)

= 1.81 ÷ 2.03

0.89x

* Primary Listing of Surface Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Surface Oncology is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Surface Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Surface Oncology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Surface Oncology expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-14.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Surface Oncology expected to grow at an attractive rate?
  • Unable to compare Surface Oncology's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Surface Oncology's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Surface Oncology's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:SURF Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:SURF Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -14.5%
NasdaqGM:SURF Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 9.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:SURF Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:SURF Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 33 -85 -100 2
2023-12-31 18 -67 -86 2
2022-12-31 8 -56 -77 3
2021-12-31 7 -40 -66 3
2020-12-31 24 -28 -38 2
2020-03-28
NasdaqGM:SURF Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 15 -60 -55
2019-09-30 25 -61 -44
2019-06-30 26 -58 -37
2019-03-31 28 -63 -15
2018-12-31 59 -13 -7
2018-09-30 52 -14 -18
2018-06-30 53 -11 -15
2018-03-31 57 22 -13
2017-12-31 13 -12 -45
2017-09-30 12 -11 -36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Surface Oncology is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Surface Oncology's revenue is expected to grow by 9.5% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:SURF Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Surface Oncology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SURF Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -1.77 -1.68 -1.85 2.00
2023-12-31 -1.71 -1.69 -1.72 2.00
2022-12-31 -1.90 -1.46 -2.53 3.00
2021-12-31 -1.89 -1.37 -2.91 3.00
2020-12-31 -1.35 -1.29 -1.41 2.00
2020-03-28
NasdaqGM:SURF Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.97
2019-09-30 -1.57
2019-06-30 -1.32
2019-03-31 -0.58
2018-12-31 -0.33
2018-09-30 -1.29
2018-06-30 -2.00
2018-03-31 -4.90
2017-12-31 -18.35
2017-09-30 -14.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Surface Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Surface Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Surface Oncology has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Surface Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Surface Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Surface Oncology does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Surface Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Surface Oncology's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Surface Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Surface Oncology Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:SURF Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 15.36 -54.79 20.61
2019-09-30 24.69 -43.57 20.32
2019-06-30 26.07 -36.84 19.31
2019-03-31 28.36 -15.14 17.81
2018-12-31 59.42 -6.61 16.08
2018-09-30 52.13 -17.66 11.78
2018-06-30 52.88 -14.85 12.46
2018-03-31 56.65 -12.66 10.55
2017-12-31 12.83 -45.42 11.03
2017-09-30 12.06 -36.44 9.49
2016-12-31 6.63 -17.49 4.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Surface Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Surface Oncology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Surface Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Surface Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Surface Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Surface Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Surface Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Surface Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Surface Oncology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Surface Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 21.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Surface Oncology Company Filings, last reported 2 months ago.

NasdaqGM:SURF Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 56.67 5.11 105.16
2019-09-30 68.99 0.00 111.80
2019-06-30 84.32 0.00 126.29
2019-03-31 100.39 0.00 140.17
2018-12-31 102.86 0.00 158.84
2018-09-30 106.02 0.00 173.38
2018-06-30 121.96 0.00 185.55
2018-03-31 27.55 0.00 93.82
2017-12-31 -18.80 0.00 63.31
2017-09-30 -3.75 0.00 79.35
2016-12-31 21.57 0.00 79.15
  • Surface Oncology's level of debt (9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Surface Oncology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Surface Oncology has sufficient cash runway for 1.7 years based on current free cash flow.
  • Surface Oncology has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 99.4% each year.
X
Financial health checks
We assess Surface Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Surface Oncology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Surface Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Surface Oncology dividends.
If you bought $2,000 of Surface Oncology shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Surface Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Surface Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:SURF Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:SURF Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Surface Oncology has not reported any payouts.
  • Unable to verify if Surface Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Surface Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Surface Oncology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Surface Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Surface Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Surface Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Surface Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Goater
COMPENSATION $4,735,765
AGE 44
TENURE AS CEO 2.1 years
CEO Bio

Mr. J. Jeffrey Goater, also known as Jeff, M.S., M.B.A, CFA has been the Chief Executive Officer and Director of Surface Oncology, Inc. since February 12, 2018 and is its President. Mr. Goater served as the Chief Business Officer of Surface Oncology, Inc. since February 7, 2017 until February 12, 2018 and Secretary from February 2017 to September 2018. Mr. Goater served as a Consultant of Voyager Therapeutics, Inc. since December 31, 2016. Mr. Goater served as the Chief Financial Officer at Voyager Therapeutics, Inc. from February 2, 2016 to December 31, 2016 and served as its Principal Financial & Accounting Officer until December 31, 2016. He served as a Senior Vice President of Finance and Business Development at Voyager Therapeutics, Inc. from April 2015 to February 2, 2016. He served as Vice President of Business Development at Voyager Therapeutics, Inc. from 2014 to April 2015. He served as an Equity Analyst at Cowen and Company, LLC, Research Division. He has nearly 15 years of business development and financial experience in the biotech industry. He served as the Head of business development at Synageva BioPharma following nine years on Wall Street and served as its Vice President of Business Development from April 2013 to July 2013. He served as Managing Director of Evercore Partners, where he focused on strategic advisory in the life sciences sector. At Evercore, he advised on $100+ billion in M&A/licensing transactions, including Sanofi's acquisition of Genzyme and Bristol-Myers Squibb's acquisition of Amylin and the subsequent sale of 50% of Bristol's interest in Amylin to AstraZeneca. He began his Wall Street career as an Equity Research Analyst at Cowen and Company covering the biopharmaceutical sector. Prior to Cowen, he worked in biotech business development and began his career as a Research Scientist in the fields of musculoskeletal biology/gene therapy. He has been a Director at Vaccinex, Inc. since May 2013. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Surface Oncology management team in years:

1.7
Average Tenure
46
Average Age
  • The average tenure for the Surface Oncology management team is less than 2 years, this suggests a new team.
Management Team

Dan Lynch

TITLE
Executive Chairman
COMPENSATION
$1M
AGE
61

Jeff Goater

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
44
TENURE
2.1 yrs

Vito Palombella

TITLE
Chief Scientific Officer
COMPENSATION
$979K
AGE
56
TENURE
4.2 yrs

Rob Ross

TITLE
Chief Medical Officer
COMPENSATION
$880K
AGE
45
TENURE
3.4 yrs

Jess Fees

TITLE
Senior VP of Finance & Treasurer
AGE
46
TENURE
1.3 yrs

Liisa Nogelo

TITLE
Secretary
AGE
47

Lisa McGrath

TITLE
Vice President of Human Resources

Wendy Dwyer

TITLE
Chief Business Officer
AGE
45
TENURE
0.9 yrs

Bob Steininger

TITLE
Senior Vice President of Chemistry

Alison O’Neill

TITLE
Senior Vice President of Clinical Development
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the Surface Oncology board of directors in years:

2.1
Average Tenure
51
Average Age
  • The average tenure for the Surface Oncology board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jeff Goater

TITLE
CEO, President & Director
COMPENSATION
$5M
AGE
44
TENURE
2.1 yrs

Dave Grayzel

TITLE
Director
COMPENSATION
$199K
AGE
50
TENURE
5.9 yrs

Dan Lynch

TITLE
Executive Chairman
COMPENSATION
$1M
AGE
61
TENURE
3.3 yrs

Geoff McDonough

TITLE
Independent Director
COMPENSATION
$382K
AGE
49
TENURE
2.1 yrs

Laurie Stelzer

TITLE
Independent Director
COMPENSATION
$361K
AGE
51
TENURE
2.1 yrs

Armen Shanafelt

TITLE
Independent Director
COMPENSATION
$205K
AGE
60
TENURE
5.3 yrs

Elliott Sigal

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$412K
AGE
67
TENURE
2.1 yrs

Steve Hodi

TITLE
Member of Scientific Advisory Board

Chris Hunter

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs

Carla Rothlin

TITLE
Member of Scientific Advisory Board
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Surface Oncology individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Feb 20 Buy J. Goater Individual 05. Feb 20 05. Feb 20 5,000 $3.23 $16,150
X
Management checks
We assess Surface Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Surface Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Many Surface Oncology, Inc. (NASDAQ:SURF) Shares Do Institutions Own?

See our latest analysis for Surface Oncology NasdaqGM:SURF Ownership Summary, July 11th 2019 What Does The Institutional Ownership Tell Us About Surface Oncology? … Insider Ownership Of Surface Oncology The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Public Company Ownership It appears to us that public companies own 14% of SURF.

Simply Wall St -

How Many Surface Oncology, Inc. (NASDAQ:SURF) Shares Do Institutions Own?

Generally speaking, as a company grows, institutions will increase their ownership. … Surface Oncology is a smaller company with a market capitalization of US$150m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that

Simply Wall St -

Is Surface Oncology Inc (NASDAQ:SURF) A Financially Sound Company?

The direct benefit for Surface Oncology Inc (NASDAQ:SURF), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is SURF right in choosing financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Is Surface Oncology Inc's (NASDAQ:SURF) Balance Sheet A Threat To Its Future?

Surface Oncology Inc (NASDAQ:SURF), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is financial flexibility worth the lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

What You Must Know About Surface Oncology Inc's (NASDAQ:SURF) Major Investors

View our latest analysis for Surface Oncology NasdaqGM:SURF Ownership_summary Apr 23rd 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … With an institutional ownership of 4.94%, SURF doesn't seem too exposed to higher volatility resulting from institutional trading. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.

Simply Wall St -

Company Info

Description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Details
Name: Surface Oncology, Inc.
SURF
Exchange: NasdaqGM
Founded: 2014
$50,790,766
28,061,197
Website: http://www.surfaceoncology.com
Address: Surface Oncology, Inc.
50 Hampshire Street,
8th Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SURF Common Stock Nasdaq Global Market US USD 19. Apr 2018
DB QSOA Common Stock Deutsche Boerse AG DE EUR 19. Apr 2018
Number of employees
Current staff
Staff numbers
49
Surface Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:51
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.